DEPRESSION IN PREGNANCY: TIME TO STOP TERRIFYING PREGNANT WOMEN

Main Article Content

Gideon Koren

Keywords

Maternal depression, pregnancy, drug therapy, risk

Abstract

Recent studies have powerfully demonstrated that women with depression, whether treated with SSRIs or skip treatment, report double risk of cardiovascular malformations. Yet, physicians and epidemiologists continue to terrify women who are at serious life threatening risks if not treated pharmacologically, with non evidence-based information. This paper calls for immediate stop of such practice.

Abstract 18 | PDF Downloads 9

References

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; ii:1358.
2. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998 Apr; 16;338(16):1128-37.
3. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol. 2012 Feb 21; [Epub ahead of print ]
4. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: metaanalysis and consideration of potential confounding factors. Clin Ther 2007;29:918- 26.
5. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012 Jun;18;2(3) pii: e001148. doi: 10.1136/bmjopen-2012-001148.
6. Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression.. Can J Psychiatry 2011 Dec;56(12):761-7.